

FOR IMMEDIATE RELEASE

AMNEAL RECEIVES FDA APPROVAL FOR ITS FIRST LIQUID RX PRODUCT, RANITIDINE HYDROCHLORIDE SYRUP

Hauppauge, NY (USA), September 2, 2008 – Amneal Pharmaceuticals is pleased to announce that it has received US FDA approval to manufacture Ranitidine Hydrochloride Syrup in 15 mg/mL strength, effective September 2, 2008. Ranitidine HCl Syrup is Amneal's first liquid ANDA and it is an AA-rated, therapeutically equivalent alternative to Zantac® (a trademark of Glaxo Group, Ltd.).

The Ranitidine Hydrochloride Syrup is the first liquid dosage form ANDA filed and approved from Amneal's Branchburg, New Jersey sterile R&D lab and manufacturing plant, which was acquired in December 2007. From this facility, Amneal has an extensive portfolio of products filed and in the development pipeline for a variety of dosage forms including liquids, nasal sprays and injectables. The production capacity of the Branchburg plant is well over seven million units per year.

Ranitidine HCl Syrup is indicated for short-term treatment of ulcers, heartburn, GERD, erosive esophagitis, and pathological hypersecretory conditions such as Zollinger-Ellison syndrome and systemic mastocytosis. Amneal will begin shipping the Ranitidine HCl Syrup in the 15 mg/mL strength as of September 8, 2008 and will have the product available through wholesalers-distributors as well as directly to the trade.

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufactures and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.

###

CONTACT: Jim Luce, Executive Vice President-Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Mobile: 949-633-2293
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
Corporate Headquarters
85 Adams Avenue
Hauppauge, NY 11788